IBM (NYSE: IBM) and Confluent, Inc. (NASDAQ: CFLT), the data streaming pioneer, today announced they have entered into a ...
Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...